Online citations, reference lists, and bibliographies.
← Back to Search

Models To Predict Intestinal Absorption Of Therapeutic Peptides And Proteins.

Filipa Antunes, Fernanda Andrade, D. Ferreira, H. M. Nielsen, B. Sarmento
Published 2013 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Prediction of human intestinal absorption is a major goal in the design, optimization, and selection of drugs intended for oral delivery, in particular proteins, which possess intrinsic poor transport across intestinal epithelium. There are various techniques currently employed to evaluate the extension of protein absorption in the different phases of drug discovery and development. Screening protocols to evaluate protein absorption include a range of preclinical methodologies like in silico, in vitro, in situ, ex vivo and in vivo. It is the careful and critical use of these techniques that can help to identify drug candidates, which most probably will be well absorbed from the human intestinal tract. It is well recognized that the human intestinal permeability cannot be accurately predicted based on a single preclinical method. However, the present social and scientific concerns about the animal well care as well as the pharmaceutical industries need for rapid, cheap and reliable models predicting bioavailability give reasons for using methods providing an appropriate correlation between results of in vivo and in vitro drug absorption. The aim of this review is to describe and compare in silico, in vitro, in situ, ex vivo and in vivo methods used to predict human intestinal absorption, giving a special attention to the intestinal absorption of therapeutic peptides and proteins.
This paper references
10.1007/s00726-007-0581-5
Correlation of in vitro and in vivo models for the oral absorption of peptide drugs
F. Föger (2007)
10.1360/982005-102
Permeation of vanadium(III, IV, V)-dipicolinate complexes across MDCK cell monolayer and comparison with Caco-2 cells
Zhang Yue (2005)
10.1166/JBN.2009.443
Improving oral absorption of Salmon calcitonin by trimyristin lipid nanoparticles.
S. Martins (2009)
10.1016/S0168-3659(99)00035-8
Transport of human growth hormone across Caco-2 cells with novel delivery agents: evidence for P-glycoprotein involvement.
S. J. Wu (1999)
10.1016/j.ejps.2010.05.002
Intestinal permeability enhancement of levothyroxine sodium by straight chain fatty acids studied in MDCK epithelial cell line.
Dimple Pabla (2010)
10.1186/1471-2105-8-245
Artificial neural network models for prediction of intestinal permeability of oligopeptides
Eunkyoung Jung (2007)
10.3109/02652040903191834
Targeted delivery of antigens to the gut-associated lymphoid tissues: 2. Ex vivo evaluation of lectin-labelled albumin microspheres for targeted delivery of antigens to the M-cells of the Peyer's patches
J. Akande (2010)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
10.1007/s11095-007-9367-4
Alginate/Chitosan Nanoparticles are Effective for Oral Insulin Delivery
B. Sarmento (2007)
10.1016/j.biomaterials.2010.04.016
Gradient cross-linked biodegradable polyelectrolyte nanocapsules for intracellular protein drug delivery.
Shujun Shu (2010)
10.1080/02652040802485725
In vitro evaluation of chondroitin sulphate-chitosan microspheres as carrier for the delivery of proteins
K. Maculotti (2009)
10.1007/s001250050081
Biochemical and morpho-cytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa
M. Bendayan (2009)
10.1016/j.addr.2012.09.005
Caco-2 monolayers in experimental and theoretical predictions of drug transport.
P. Artursson (2001)
10.2174/1568026013394886
Strategies for absorption screening in drug discovery and development.
H. Bohets (2001)
10.1002/jps.21912
Absorption barriers in the rat intestinal mucosa: 1. Application of an in situ perfusion model to simultaneously assess drug permeation and metabolism.
D. Mudra (2010)
10.1002/JPS.1111
HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer.
C. Pontier (2001)
10.1007/s13346-011-0023-5
Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin
P. Fonte (2011)
10.1016/j.jconrel.2010.02.001
A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa.
Abdallah Makhlof (2011)
10.1016/j.jconrel.2009.02.015
Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides.
N. Kamei (2009)
10.1021/JM049711O
Exploring the role of different drug transport routes in permeability screening.
P. Matsson (2005)
10.1023/B:PHAM.0000033013.45204.c3
Cellular Uptake But Low Permeation of Human Calcitonin-Derived Cell Penetrating Peptides and Tat(47-57) Through Well-Differentiated Epithelial Models
Rachel Tréhin (2004)
10.1517/17425255.4.5.581
Prediction of oral drug absorption in humans – from cultured cell lines and experimental animals
K-C Cheng (2008)
10.1208/s12249-010-9390-3
Insulin-Loaded Nanoparticles Based on N-Trimethyl Chitosan: In Vitro (Caco-2 Model) and Ex Vivo (Excised Rat Jejunum, Duodenum, and Ileum) Evaluation of Penetration Enhancement Properties
G. Sandri (2010)
10.1016/j.etap.2005.06.002
Predicting oral drug absorption and hepatobiliary clearance: Human intestinal and hepatic in vitro cell models.
Richard A Fearn (2006)
10.1248/BPB.33.111
Investigation of the intestinal permeability and first-pass metabolism of drugs in cynomolgus monkeys using single-pass intestinal perfusion.
M. Takahashi (2010)
10.1002/BDD.2510160502
Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals
T. Kararli (1995)
Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells.
T. Lesuffleur (1990)
10.1016/j.ejpb.2008.03.004
Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells.
A. Sadeghi (2008)
10.1038/nrd1695
Protein drug stability: a formulation challenge
S. Frokjaer (2005)
10.1002/(SICI)1520-6017(200001)89:1<63::AID-JPS7>3.0.CO;2-6
Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.
C. Hilgendorf (2000)
10.1016/j.ijpharm.2007.12.037
Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies.
A. Bayat (2008)
10.2174/092986706778201558
Recent advances in computational prediction of drug absorption and permeability in drug discovery.
T. Hou (2006)
10.1016/J.IJPHARM.2007.07.035
In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery.
Fu Chen (2008)
10.1016/S0928-0987(99)00032-9
Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement.
N. G. Schipper (1999)
10.1615/CRITREVTHERDRUGCARRIERSYST.V19.I2.20
Oral delivery of proteins: progress and prognostication.
R. Shah (2002)
10.1021/JS970218S
Membrane transport of drugs in different regions of the intestinal tract of the rat.
A. Ungell (1998)
10.1021/JS960110X
HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans.
E. Walter (1996)
10.1007/s002280100369
In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report
O. Pelkonen (2001)
10.1016/j.ejps.2009.11.002
Transport of chitosan-DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes.
I. Kadiyala (2010)
10.1016/j.biomaterials.2010.01.045
Polymer integrity related absorption mechanism of superporous hydrogel containing interpenetrating polymer networks for oral delivery of insulin.
Lichen Yin (2010)
10.1002/DDR.10423
Enhancing effect of chemically conjugated deoxycholic acid on permeability of calcitonin in Caco‐2 cells
Sunhee Kim (2005)
10.1016/J.EJPS.2004.11.007
In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media.
V. H. Sunesen (2005)
10.1248/BPB.16.68
Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin.
M. Morishita (1993)
10.1016/J.EJPS.2005.07.004
Canine versus in vitro data for predicting input profiles of L-sulpiride after oral administration.
N. Fotaki (2005)
10.1016/J.MSEB.2009.09.007
Uptake and cytotoxicity of poly(d,l-lactide-co-glycolide) nanoparticles in human colon adenocarcinoma cells
A. Katsikari (2009)
10.1177/026119290102900604
In Vitro Models of the Intestinal Barrier
E. Le Ferrec (2001)
10.1211/0022357011775217
Secretory transport of p‐aminohippuric acid across intestinal epithelial cells in Caco‐2 cells and isolated intestinal tissue
K. Naruhashi (2001)
10.1021/bp0101379
pH‐Sensitive Hydrogels as Gastrointestinal Tract Absorption Enhancers: Transport Mechanisms of Salmon Calcitonin and Other Model Molecules Using the Caco‐2 Cell Model
M. Torres-Lugo (2002)
10.1016/J.ADDR.2004.02.013
Companion animal physiology and dosage form performance.
S. C. Sutton (2004)
10.1023/A:1015911712079
In Vitro Measurement of Gastrointestinal Tissue Permeability Using a New Diffusion Cell
G. Grass (2004)
10.1023/A:1015807904558
The Madin Darby Canine Kidney (MDCK) Epithelial Cell Monolayer as a Model Cellular Transport Barrier
Moo J. Cho (2004)
10.1007/s11095-006-9041-2
Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model
X. Cao (2006)
10.1016/S0169-409X(98)00041-6
Evaluation of nano- and microparticle uptake by the gastrointestinal tract.
Delie (1998)
10.1016/j.jconrel.2010.02.017
Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats.
Yulian Lin (2011)
10.1016/J.JCONREL.2006.06.011
Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination.
O. Borges (2006)
10.1042/CS0730053
A comparison of the structural integrity of several commonly used preparations of rat small intestine in vitro.
J. Plumb (1987)
10.1021/JS950267+
Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue.
W. Rubas (1996)
10.1016/S0169-409X(02)00004-2
Prediction of intestinal permeability.
W. J. Egan (2002)
10.1016/S1056-8719(00)00113-1
Current methodologies used for evaluation of intestinal permeability and absorption.
P. Balimane (2000)
10.1159/000162930
Establishment of human colon carcinoma lines in nude mice.
J. Fogh (1979)
10.1002/JPS.21010
Variability in Caco-2 and MDCK cell-based intestinal permeability assays.
D. Volpe (2008)
10.1007/s11095-004-9007-1
In Vitro and ex Vivo Intestinal Tissue Models to Measure Mucoadhesion of Poly (Methacrylate) and N-Trimethylated Chitosan Polymers
S. Keely (2004)
10.1006/EXCR.2000.4920
Different functional recognition of basolateral signals in Caco-2 and MDCK cells.
L. Monlauzeur (2000)
10.1016/j.ddtec.2004.09.004
Predicting the intestinal absorption potential of hits and leads.
M. Hämäläinen (2004)
10.1023/A:1016065715308
Comparison Between Permeability Coefficients in Rat and Human Jejunum
U. Fagerholm (2004)
10.1007/S12257-009-3058-4
Strategies for oral delivery of macromolecule drugs
J. Park (2010)
A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: active efflux transport as a cause of poor bioavailability of the active drug.
N. Okudaira (2000)
10.1016/J.ADDR.2007.06.016
Animal data: the contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivo.
H. Lennernäs (2007)
10.1126/SCIENCE.277.5328.949
Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria.
S. Kernéis (1997)
10.1016/J.IJPHARM.2006.02.053
Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant.
Shinya Takatsuka (2006)
10.1016/J.JCONREL.2006.08.013
Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.
A. des Rieux (2006)
10.1016/S0169-409X(01)00152-1
Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics.
N. Hussain (2001)
Oral insulin delivery by means of solid lipid nanoparticles
B. Sarmento (2007)
10.1002/jps.21965
Absorption barriers in the rat intestinal mucosa: 2. Application of physiologically based mathematical models to quantify mechanisms of drug permeation and metabolism.
D. Mudra (2010)
10.1111/J.1748-1716.1951.TB00800.X
Active transport of sodium as the source of electric current in the short-circuited isolated frog skin.
H. Ussing (1951)
10.1016/0168-3659(96)01352-1
Structural requirements for intestinal absorption of peptide drugs
G. Pauletti (1996)
Cell cultures as models for drug absorption across the intestinal mucosa.
P. Artursson (1991)
10.1080/10611860701639848
Microparticle transport in the human intestinal M cell model
Y. Lai (2008)
In vitro - in vivo correlation: from theory to applications.
J. Emami (2006)
10.1586/17512433.2.2.195
Pros and cons of methods used for the prediction of oral drug absorption
N. Fotaki (2009)
10.1016/S1056-8719(00)00107-6
Drug-like properties and the causes of poor solubility and poor permeability.
C. Lipinski (2000)
10.1016/J.IJPHARM.2005.01.022
Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium.
Nazila Salamat-Miller (2005)
10.1016/j.ejps.2009.10.005
Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption.
P. Annaert (2010)
10.1007/978-0-387-74901-3
Drug Absorption Studies
C. Ehrhardt (2008)
10.1016/j.actbio.2009.05.032
The effect of complexation hydrogels on insulin transport in intestinal epithelial cell models.
K. Wood (2010)
10.1007/s00125-001-0751-z
Self-assembled “nanocubicle” as a carrier for peroral insulin delivery
H. Chung (2001)
10.1002/9783527611225.ch18
In silico prediction models for blood-brain barrier permeation.
G. Ecker (2004)
10.1016/S0928-0987(00)00073-7
Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: importance of drug ionisation in the in vitro prediction of in vivo absorption.
M. Boisset (2000)
10.1186/1471-2121-7-20
Development of a serum-free co-culture of human intestinal epithelium cell-lines (Caco-2/HT29-5M21)
Géraldine Nollevaux (2006)
10.1021/MP0500768
Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery.
Shuanghui Luo (2006)
10.1016/0928-0987(95)00010-B
Heterogeneity in the human intestinal cell line Caco-2 leads to differences in transepithelial transport
E. Walter (1995)
10.1208/s12248-009-9098-z
Mechanistic Approaches to Predicting Oral Drug Absorption
W. Huang (2009)
10.1016/j.actbio.2010.02.007
Thiol functionalized polymethacrylic acid-based hydrogel microparticles for oral insulin delivery.
S. Sajeesh (2010)
10.1016/j.ejps.2010.08.009
Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles.
Camile B. Woitiski (2010)
10.1016/0928-0987(95)00007-Z
Co-cultures of human intestinal goblet (HT29-H) and absorptive (Caco-2) cells for studies of drug and peptide absorption
A. Wikman-Larhed (1995)
10.1208/s12249-010-9399-7
In vitro Permeability Enhancement in Intestinal Epithelial Cells (Caco-2) Monolayer of Water Soluble Quaternary Ammonium Chitosan Derivatives
Jariya Kowapradit (2010)
10.1023/A:1016169202830
Comparison of Oral Absorption and Bioavailability of Drugs Between Monkey and Human
W. Chiou (2004)
10.1002/(SICI)1097-0029(20000515)49:4<346::AID-JEMT3>3.0.CO;2-B
Intestinal absorption of peptides through the enterocytes
E. Ziv (2000)
10.1021/JS9803205
MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening.
J. D. Irvine (1999)
10.1016/J.EJPS.2006.12.006
An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells.
A. des Rieux (2007)
10.1080/1061186021000038319
Transport of Chitosan Microparticles for Mucosal Vaccine Delivery in a Human Intestinal M-cell Model
I. M. van der Lubben (2002)
10.1016/S0928-0987(00)00181-0
In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs.
J. Dressman (2000)
10.1016/j.jconrel.2009.04.022
Transepithelial transport of PEGylated anionic poly(amidoamine) dendrimers: implications for oral drug delivery.
D. Sweet (2009)
10.1021/jm901846t
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
A. Avdeef (2010)
10.1111/j.2042-7158.1996.tb03952.x
Development and Validation of a Pig Model for Colon‐specific Drug Delivery
N. Gardner (1996)
10.1016/S0167-7799(97)01170-0
Innovative strategies for the oral delivery of drugs and peptides.
A. Fasano (1998)
10.1023/A:1013647114152
Comparison of Bidirectional Cephalexin Transport Across MDCK and Caco-2 Cell Monolayers: Interactions with Peptide Transporters
W. Putnam (2004)
10.1038/nrd1067
Challenges for the oral delivery of macromolecules
M. Goldberg (2003)
10.1016/J.JCONREL.2006.12.023
Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium.
A. des Rieux (2007)
10.1021/BM0703923
Oral bioavailability of insulin contained in polysaccharide nanoparticles.
B. Sarmento (2007)
10.1080/03639040601011231
Transport of Insulin in Modified Valia-Chien Chambers and Caco-2 Cell Monolayers
Cui Tang (2007)
10.1016/S0169-409X(96)00415-2
Caco-2 monolayers in experimental and theoretical predictions of drug transport
P. Artursson (1996)
10.1016/S1461-5347(98)00010-8
Cassette dosing: rapid in vivo assessment of pharmacokinetics
L. Frick (1998)
10.1016/j.addr.2009.06.003
Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics.
R. Gaspar (2009)
10.1002/jbm.a.32395
Assessment of poly(methacrylic acid-co-N-vinyl pyrrolidone) as a carrier for the oral delivery of therapeutic proteins using Caco-2 and HT29-MTX cell lines.
D. A. Carr (2010)
10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
Intestinal permeation enhancers.
B. Aungst (2000)
10.1016/S1359-6446(04)03354-9
Cell culture-based models for intestinal permeability: a critique.
P. Balimane (2005)
10.1124/dmd.106.013862
Intestinal First-Pass Metabolism via Carboxylesterase in Rat Jejunum and Ileum
K. Masaki (2007)
10.1208/s12248-008-9027-6
In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms
J. Polli (2008)
10.1016/j.ijpharm.2009.12.022
Impact of amino acid replacements on in vitro permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin.
S. Maher (2010)
10.1163/156856207794761989
Complexation hydrogels for oral protein delivery: an in vitro assessment of the insulin transport-enhancing effects following dissolution in simulated digestive fluids
E. Perakslis (2007)
10.1006/BBRC.2000.4038
Expression of specific markers and particle transport in a new human intestinal M-cell model.
E. Gullberg (2000)
10.1007/978-0-387-74901-3_8
In Vitro Screening Models to Assess Intestinal Drug Absorption and Metabolism
S. Deferme (2008)
10.1002/mabi.200900223
Cellular evaluation of synthesized insulin/transferrin bioconjugates for oral insulin delivery using intelligent complexation hydrogels.
Justin P. Shofner (2010)
10.1023/A:1016217505990
Possible Involvement of Multiple P-Glycoprotein-Mediated Efflux Systems in the Transport of Verapamil and Other Organic Cations Across Rat Intestine
H. Saitoh (2004)
10.1007/s11095-007-9246-z
Melittin as a Permeability Enhancer II: In Vitro Investigations in Human Mucus Secreting Intestinal Monolayers and Rat Colonic Mucosae
S. Maher (2007)
10.1034/J.1600-0773.2002.900601.X
Transport of peptidomimetic drugs by the intestinal Di/tri-peptide transporter, PepT1.
B. Brodin (2002)
10.1016/S0223-5234(03)00015-1
Evaluation of rat intestinal absorption data and correlation with human intestinal absorption.
Y. Zhao (2003)
10.1016/J.EJPS.2005.02.008
A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery.
M. Garcia-Fuentes (2005)
10.1208/aapsj060431
Regional permeability of salmon calcitonin in isolated rat gastrointestinal tracts: Transport mechanism using Caco-2 cell monolayer
R. Shah (2008)
10.1002/jps.22080
Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay.
S. Skolnik (2010)
Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics.
J. Lin (1998)
10.1016/S0165-6147(02)02072-2
Mammalian peptide transporters as targets for drug delivery.
I. Rubio-Aliaga (2002)
10.1073/PNAS.0400969101
Intestinal villous M cells: an antigen entry site in the mucosal epithelium.
M. H. Jang (2004)
10.1046/J.1365-201X.1998.0248F.X
Integrity and metabolism of human ileal mucosa in vitro in the Ussing chamber.
J. Söderholm (1998)



This paper is referenced by
Drug absorption enhancement capacities and mechanisms of action of Aloe vera gel materials
Anja Haasbroek (2018)
Gastrointestinal region specific insulin absorption enhancement by Aloe vera leaf materials
E. Pretorius (2015)
10.1208/s12249-016-0522-2
In Vitro and Ex Vivo Evaluations of Lipid Anti-Cancer Nanoformulations: Insights and Assessment of Bioavailability Enhancement
A. Jain (2016)
10.1016/j.jconrel.2019.10.053
Pharmaceutical strategies of improving oral systemic bioavailability of curcumin for clinical application.
Ziwei Ma (2019)
10.7324/japs.2018.81115
Intestinal permeability studies for piperaquine from dihydroartemisinin — piperaquine antimalarial product in the presence of lamivudine
A. Agboke (2018)
Neurotensin:a candidate for peptide-guideddrug delivery
J. Bird (2015)
10.1111/1541-4337.12402
Meta‐Analysis for Correlating Structure of Bioactive Peptides in Foods of Animal Origin with Regard to Effect and Stability
E. Maestri (2019)
10.1016/j.jprot.2016.03.048
Bioactive peptides in plant-derived foodstuffs.
E. Maestri (2016)
10.1016/j.ijpharm.2013.10.003
Towards the characterization of an in vitro triple co-culture intestine cell model for permeability studies.
F. Araújo (2013)
REVIEW ON NOVEL APPROACHES FOR ORAL PROTEIN AND PEPTIDE DRUG DELIVERY
Diksha Pandita (2018)
10.1016/j.ejpb.2017.04.004
Transport of curcumin derivatives in Caco‐2 cell monolayers
Z. Zeng (2017)
10.1371/journal.pone.0119471
The Quorum Sensing Peptides PhrG, CSP and EDF Promote Angiogenesis and Invasion of Breast Cancer Cells In Vitro
B. De Spiegeleer (2015)
Screening and purification of bioactive peptides with potential to activate the cholecystokinin receptor type 1
D. Staljanssens (2013)
10.7324/japs.2020.1010017
Non-invasive strategies for protein drug delivery: Oral, transdermal, and pulmonary
M. I. Irianti (2020)
Real-time electrochemical detection of paracetamol interaction with intestinal tissue
S. Rajendran (2018)
10.3389/fbioe.2019.00144
Advances and Current Challenges in Intestinal in vitro Model Engineering: A Digest
J. Costa (2019)
10.1016/J.JFCA.2017.01.011
Transepithelial transport of lunasin and derived peptides: Inhibitory effects on the gastrointestinal cancer cells viability
S. Fernández-Tomé (2017)
10.1089/can.2017.0032
Cannabidiol Does Not Convert to Δ9-Tetrahydrocannabinol in an In Vivo Animal Model
Louise Wray (2017)
10.3390/polym8060214
Functionalized Polymers for Enhance Oral Bioavailability of Sensitive Molecules
Y. A. Pérez (2016)
10.3390/molecules23112990
Impact of Sodium N-[8-(2-Hydroxybenzoyl)amino]-caprylate on Intestinal Permeability for Notoginsenoside R1 and Salvianolic Acids in Caco-2 Cells Transport and Rat Pharmacokinetics
Y. Li (2018)
10.1517/17425255.2015.980814
Applying machine learning techniques for ADME-Tox prediction: a review
V. Maltarollo (2015)
10.1016/J.FOODRES.2014.01.069
Peptidomics for discovery, bioavailability and monitoring of dairy bioactive peptides
Laura Sánchez-Rivera (2014)
Investigation of surfactant-drug pharmacokinetic interactions
L. Erasmus (2018)
10.3384/DISS.DIVA-100770
Role of mast cells and probiotics in the regulation of intestinal barrier function
A. Carlsson (2013)
10.2174/157488611798918719
Relaxin as a cardiovascular drug: a promise kept.
D. Bani (2011)
Pharmacokinetic interactions: the effect of herbal extracts and supplements on drug permeation
C. Jacobsz (2018)
10.1080/17425255.2019.1621289
Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs
S. Banerjee (2019)
10.1016/j.biomaterials.2015.03.054
Dissecting stromal-epithelial interactions in a 3D in vitro cellularized intestinal model for permeability studies.
C. Pereira (2015)
Establishment of a cellularized artificial model of the gastric wall
João Q. Coentro (2014)
10.1517/17425255.2013.802772
Experimental models for predicting drug absorption and metabolism
S. Alqahtani (2013)
10.1016/j.ejpb.2012.10.003
Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs.
Filipa Antunes (2013)
10.1002/bdd.1940
Investigation of omeprazole and phenacetin first‐pass metabolism in humans using a microscale bioreactor and pharmacokinetic models
Thibault Bricks (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar